Pfizer (PFE) Equity Ratio (2009 - 2026)

Pfizer has disclosed Equity Ratio across 18 years of filings, most recently posting 0.43 for Q1 2026.

• In Q1 2026, Equity Ratio fell 0.58% year-over-year to 0.43; the TTM figure through Mar 2026 stood at 0.43 (down 0.58% YoY), while the FY2025 annual figure was 0.42, changed 0.17% from the prior year.
• Equity Ratio advanced to 0.43 in Q1 2026, from 0.42 in the prior quarter.
• Over the last five years, Equity Ratio for PFE reached as high as 2.26 in Q4 2022 and fell as low as 0.39 in Q4 2023.
• The 5-year median for Equity Ratio is 0.44 (2025), against an average of 0.55.
• Annual changes were most pronounced in 2022 — Equity Ratio surged 190.76% — and 2023, when it slumped 79.98%.
• A 5-year view of Equity Ratio shows it stood at 0.49 in 2022, then slipped by 19.03% to 0.39 in 2023, then advanced by 5.2% to 0.41 in 2024, then advanced by 0.17% to 0.42 in 2025, then climbed by 4.27% to 0.43 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.43, 0.42, and 0.45 for Q1 2026, Q4 2025, and Q3 2025 respectively.